The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.
about
Misregulation of pre-mRNA alternative splicing in cancerCancer-relevant Splicing Factor CAPERĪ± Engages the Essential Splicing Factor SF3b155 in a Specific Ternary ComplexMicrobial and Natural Metabolites That Inhibit Splicing: A Powerful Alternative for Cancer TreatmentAberrant splicing and drug resistance in AMLStructural and mechanistic insights into human splicing factor SF3b complex derived using an integrated approach guided by the cryo-EM density mapsThe splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.Alternative splicing and retinal degenerationA high-throughput splicing assay identifies new classes of inhibitors of human and yeast spliceosomesRole of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosisInhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicingTargeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates.USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer.Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1)Herboxidiene triggers splicing repression and abiotic stress responses in plants.The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.RNA splicing factors as oncoproteins and tumour suppressors.Design, synthesis and in vitro splicing inhibition of desmethyl and carba-derivatives of herboxidieneSplicing factor mutations in myelodysplasia.Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.Alternative splicing in cancer: implications for biology and therapy.Pre-mRNA splicing-modulatory pharmacophores: the total synthesis of herboxidiene, a pladienolide-herboxidiene hybrid analog and related derivatives.Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems.Therapeutic targeting of splicing in cancer.Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability.Splicing factor gene mutations in hematologic malignancies.Characterisation of the biflavonoid hinokiflavone as a pre-mRNA splicing modulator that inhibits SENP.Optimization of antitumor modulators of pre-mRNA splicing.Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.Re2 O7 -Mediated Dehydrative Cyclization Reactions: Total Synthesis of Herboxidiene and Its 12-Desmethyl Analogue.A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.CRISPR/Cas9-mediated target validation of the splicing inhibitor Pladienolide B.Identification and characterization of aberrant GAA pre-mRNA splicing in pompe disease using a generic approach.
P2860
Q27007114-A7909A08-01A7-444C-ADA4-4125B76A53C4Q27683637-FBE40DC7-E3F1-40CF-90FD-EC894184B722Q28074931-1C8EBDB5-803B-4B00-8EC3-BE8E58A9A946Q28076011-93373A23-AC29-44C7-9F07-499D6EFD971EQ28315106-94D09D6B-804E-43B8-A8D3-46A701BE1035Q30395427-4ABCED7B-C936-4771-8EDA-6BA661702D8DQ34102442-7FCA2FDA-5A82-4985-805C-48A96D4348DBQ34774635-A30D51CC-D034-4619-BAFC-D145D89BACBCQ35442986-FF8807AF-3B10-47DB-9F70-750B501A841CQ35541632-63592BE8-064F-4F53-BF52-167B83EF3FBFQ35800840-FE8D314E-CF4A-42D0-A9D2-E3E5C14D33A5Q35822289-4638E887-E5C5-44EB-BEFE-294AED627FF9Q36268425-34AB121B-5C3F-4FBF-94E5-297579A8274BQ36280761-3FB9CDA4-ACB8-4D89-8813-FC834DAC8F17Q36324293-33D2D5E3-CF36-4112-8BE6-548E059C51B2Q36410173-63D5ED02-0E7B-4FAD-998D-84EE902E6217Q36584775-5A5FF1E1-1122-47D1-AC87-48C3FB127BA5Q37304724-4C8A45D7-34B4-4010-A8D4-A10CD38D7CA7Q37391660-DE1F35B6-EB4D-47E6-B565-3F59BCB675A4Q37677391-F4C6F4D6-F00A-4853-B67F-C7F1DBEDDE83Q38051189-B399E3E8-A536-4A27-9A74-EB5F0EFFA30BQ38060535-A380E0DD-24A0-4CE9-B163-8DBD481B56F3Q38179828-22654DC8-70BD-48EE-ACD8-D6FD9D529D16Q38406831-F9000A6D-9181-4407-9E77-DD4F42D6C7AAQ38735423-96EA78C6-3661-444C-9416-2B1B89186B17Q38948363-BC518B18-0254-4FDA-A3D4-66FB78AD5E6AQ38972458-B26FEB49-3252-480A-AA56-A22B0F31FAEFQ39035441-E69EC9C0-B396-4F78-9D2A-5EE570758FA9Q41664870-7F292967-611C-4B8F-A519-F1EE505BC9AEQ41973693-EF29B27D-9E71-4D00-B8BF-A177056A25CAQ44770380-495EBB2C-B64E-4CB1-AEA8-87FE6888C7E0Q47784889-E676B25E-6373-49DF-879D-A568CC89F793Q48159101-7471A1FC-6817-4A5A-951D-7DE4386D5C20Q51220040-00942123-1ECD-4AEB-B528-2DFFD24E55CFQ52430362-B88200DD-C46B-42F6-BF13-2B387BD6CBBAQ54191134-5170886F-0D18-4401-ABE6-1341F4E292AD
P2860
The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.
description
article cientĆfic
@ca
article scientifique
@fr
articol ČtiinČific
@ro
articolo scientifico
@it
artigo cientĆfico
@gl
artigo cientĆfico
@pt
artigo cientĆfico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artĆculo cientĆfico
@es
name
The development and applicatio ...... therapeutic agents for cancer.
@en
type
label
The development and applicatio ...... therapeutic agents for cancer.
@en
prefLabel
The development and applicatio ...... therapeutic agents for cancer.
@en
P2860
P1433
P1476
The development and applicatio ...... therapeutic agents for cancer
@en
P2093
Amanda S Joyner
Thomas R Webb
P2860
P356
10.1016/J.DRUDIS.2012.07.013
P577
2012-08-03T00:00:00Z